SEC Form 4 · accession 0001144204-15-020400
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barbara Gayle Duncan
Officer — Chief Financial Officer
Period of report
Mar 27, 2015
Accepted (ET)
Apr 1, 2015 · 10:00 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 27, 2015 | S | 100 | $285.00 | D | 17,164 | D | |
| Common Stock | Mar 27, 2015 | S | 100 | $286.00 | D | 17,064 | D | |
| Common Stock | Mar 27, 2015 | S | 100 | $287.00 | D | 16,964 | D | |
| Common Stock | Mar 27, 2015 | S | 100 | $288.00 | D | 16,864 | D | |
| Common Stock | Mar 27, 2015 | S | 100 | $289.00 | D | 16,764 | D | |
| Common Stock | Mar 27, 2015 | S | 100 | $291.00 | D | 16,664 | D | |
| Common Stock | Mar 27, 2015 | S | 100 | $292.16 | D | 16,564 | D | |
| Common StockF1 | Mar 27, 2015 | S | 300 | $293.3375 | D | 16,264 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $293.00 to $293.5600. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.